MON-183 Adrenal Androgen Control and Steroidal Side Effects in Adolescents and Adults with Congenital Adrenal Hyperplasia Treated with Glucocorticoids

por Falhammar, Henrik, Farber, Robert, Chan, Jean L, Farrar, Mallory, Yonan, Chuck, Kuranz, Seth, Auchus, Richard J
Publicado 2020

Noninvasive predictors of clinically significant portal hypertension in NASH cirrhosis: Validation of ANTICIPATE models and development of a lab‐based model

por Rabiee, Anahita, Deng, Yanhong, Ciarleglio, Maria, Chan, Jean L., Pons, Monica, Genesca, Joan, Garcia‐Tsao, Guadalupe
Publicado 2022

Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non‐alcoholic fatty liver disease

por Shiffman, Mitchell, Freilich, Bradley, Vuppalanchi, Raj, Watt, Kymberly, Chan, Jean L., Spada, Al, Hagerty, David T., Schiff, Eugene
Publicado 2018

Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia

por Auchus, Richard J, Sarafoglou, Kyriakie, Fechner, Patricia Y, Vogiatzi, Maria G, Imel, Erik A, Davis, Shanlee M, Giri, Nagdeep, Sturgeon, Julia, Roberts, Eiry, Chan, Jean L, Farber, Robert H
Publicado 2021

Crinecerfont, a CRF(1) Receptor Antagonist, Lowers Adrenal Androgens in Adolescents With Congenital Adrenal Hyperplasia

por Newfield, Ron S, Sarafoglou, Kyriakie, Fechner, Patricia Y, Nokoff, Natalie J, Auchus, Richard J, Vogiatzi, Maria G, Jeha, George S, Giri, Nagdeep, Roberts, Eiry, Sturgeon, Julia, Chan, Jean L, Farber, Robert H
Publicado 2023

Emricasan (IDN‐6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension

por Garcia‐Tsao, Guadalupe, Fuchs, Michael, Shiffman, Mitchell, Borg, Brian B., Pyrsopoulos, Nikolaos, Shetty, Kirti, Gallegos‐Orozco, Juan F., Reddy, K. Rajender, Feyssa, Eyob, Chan, Jean L., Yamashita, Mason, Robinson, James M., Spada, Alfred P., Hagerty, David T., Bosch, Jaime
Publicado 2018